FORT DETRICK, Md., April 22, 2021 – The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) announced today that its Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR) Repurposing Framework (RF) won a Bronze Edison Award in the "Innovative Services, Prescription Drug Access Platforms” category. The Edison Best New Product Awards™ is an annual competition honoring excellence in new product and service development, marketing, human-centered design, and innovation. Award winners represent "game changing" products and services, as well as excellence and leadership in innovation.
The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures (MCMs) and systems to enhance the nation’s biodefense response capability. During the pandemic, a new weapon in its arsenal has come to the forefront: the RAIDR RF, a process which facilitates the rapid delivery of existing MCMs to the warfighter, as needed.
The RAIDR RF identifies the utility and supporting data if an MCM will make a successful repurposing candidate, keeping track of the MCMs and the associated literature that supports them, and quickly documenting findings and providing recommendations to the DOD and other implementing organizations. This is beneficial as the cost and risk of repurposing an MCM are both low, relative to the development of a novel compound or device, since they have an accepted safety profile and are already in production; they are also more sustainable, having existing infrastructures and supply chains.
Being selected as a Bronze Edison Award winner is one of the highest accolades an organization can receive in the name of innovation and business success. Selection validates work performed by the JPM CBRN Medical team to find new and innovative ways to deliver MCMs to the warfighter.
Read more about the JPM CBRN Medical’s 2021 Edison Award win at https://www.jpeocbrnd.osd.mil/raidr/
About the JPM CBRN Medical: The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability.
About the JPEO-CBRND: The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense is the Joint Service’s lead for development, acquisition, fielding and life-cycle support of chemical, biological, radiological, and nuclear defense equipment and medical countermeasures. As an effective acquisition program, the JPEO-CBRND puts capable and supportable systems in the hands of the service members and first responders, when and where it is needed, at an affordable price. Our vision is a resilient Joint Force, enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment, championed by innovative and state-of-the-art solutions.